- Home
- NMM vs NTLA Comparison
NMM vs NTLA Comparison
Compare NMM & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NTLA
- Stock Information
- Founded
- NMM 2007
- NTLA 2014
- Country
- NMM Greece
- NTLA United States
- Employees
- NMM N/A
- NTLA N/A
- Industry
- NMM Marine Transportation
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NMM Consumer Discretionary
- NTLA Health Care
- Exchange
- NMM Nasdaq
- NTLA Nasdaq
- Market Cap
- NMM 1.4B
- NTLA 1.2B
- IPO Year
- NMM 2007
- NTLA 2016
- Fundamental
- Price
- NMM $48.42
- NTLA $12.41
- Analyst Decision
- NMM Strong Buy
- NTLA Buy
- Analyst Count
- NMM 1
- NTLA 20
- Target Price
- NMM $80.00
- NTLA $32.30
- AVG Volume (30 Days)
- NMM 119.4K
- NTLA 4.2M
- Earning Date
- NMM 11-04-2025
- NTLA 11-06-2025
- Dividend Yield
- NMM 0.41%
- NTLA N/A
- EPS Growth
- NMM N/A
- NTLA N/A
- EPS
- NMM 10.24
- NTLA N/A
- Revenue
- NMM $1,305,026,000.00
- NTLA $52,857,000.00
- Revenue This Year
- NMM N/A
- NTLA $8.32
- Revenue Next Year
- NMM $7.93
- NTLA N/A
- P/E Ratio
- NMM $4.72
- NTLA N/A
- Revenue Growth
- NMM N/A
- NTLA 14.99
- 52 Week Low
- NMM $28.37
- NTLA $5.90
- 52 Week High
- NMM $65.89
- NTLA $23.76
- Technical
- Relative Strength Index (RSI)
- NMM 63.15
- NTLA 62.53
- Support Level
- NMM $47.11
- NTLA $10.89
- Resistance Level
- NMM $49.59
- NTLA $12.03
- Average True Range (ATR)
- NMM 1.11
- NTLA 0.73
- MACD
- NMM -0.12
- NTLA 0.09
- Stochastic Oscillator
- NMM 65.49
- NTLA 68.85
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.